gms | German Medical Science

70. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Skandinavischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

12.05. - 15.05.2019, Würzburg

The influence of distinct regulatory miRNAs of the p15/p16/RB1/E2F pathway on the clinical progression of glioblastoma multiforme

Über den Einfluss spezifischer regulatorischer miRNAs des p15/p16/RB1/E2F Signalweges auf den klinischen Verlauf einer Glioblastomerkrankung

Meeting Abstract

  • presenting/speaker Christoph Sippl - Universitätsklinikum des Saarlandes, Neuropathologie, Homburg, Deutschland
  • Steffi Urbschat - Universitätsklinikum des Saarlandes, Klinik für Neurochiurgie, Homburg, Deutschland
  • Ketter Ralf - Universitätsklinikum des Saarlandes, Klinik für Neurochiurgie, Homburg, Deutschland
  • Walter Schulz-Schaeffer - Universitätsklinikum des Saarlandes, Neuropathologie, Homburg, Deutschland
  • Luisa Braun - Universitätsklinikum des Saarlandes, Klinik für Neurochiurgie, Homburg, Deutschland
  • Joachim Oertel - Universitätsklinikum des Saarlandes, Klinik für Neurochiurgie, Homburg, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 70. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Skandinavischen Gesellschaft für Neurochirurgie. Würzburg, 12.-15.05.2019. Düsseldorf: German Medical Science GMS Publishing House; 2019. DocV254

doi: 10.3205/19dgnc273, urn:nbn:de:0183-19dgnc2737

Published: May 8, 2019

© 2019 Sippl et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.


Outline

Text

Objective: Glioblastoma is the most common malignant brain tumor in adults and has a very poor prognosis. The microRNAs (miRNA) -26a, -24, and -21 have been reported as regulators of the p15/p16/RB1/E2F pathway which play a major role in glioblastoma progression. The present study aimed to evaluate their appliance as predictive markers for the progression of glioblastoma multiforme.

Methods: Using the PCR-based comparative 2-∆Ct CT method, the expression of miRNA-26a, -24, and -21 was analyzed in tumor specimens of 104 glioblastoma patients. All tumors were tested for p15, p16, RB1, and MGMT promoter methylation as well as IDH1 R132H mutation status. The results were examined with individual clinical data as well as with progression-free and overall survival. Brain tissue specimens from eight donors without neoplasms served as healthy controls.

Results: The FC (fold change) of miRNA-21, -24, and -26a was 1.51±1.35, 0.75±0.67 and 0.39±0.24 in the tumor samples. In the control group FC of miRNA-21, -24, and -26a was 0.31±0.51, 0.66±0.33 and 0.18±0.11 respectively. MiRNA-26a and -21 were significantly overexpressed in glioblastoma samples in comparison to healthy brain tissue (miRNA-21: p<0.001; miRNA-26a: p=0.011). High miRNA-24 expression was trended for a prolonged overall survival (p=0.07). Patients with high miRNA-26a expression had longer progression-free survival (HR 0.21 [95% CI: 0.09–0.51], p<0.001) and overall survival (HR 0.3 [95% CI: 0.136–0.682], p=0.003). Gross total resection significantly extended overall survival (p=0.003).

Conclusion: miRNA-26a and -24 expression is a promising predictor of the progression of glioblastoma and should be further evaluated.